AMGN AM

AMGN Amgen Inc.

Healthcare · Drug Manufacturers - General

6 · Aceptable Vigilar racha de 14a

358.33

+1.56%

Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

2.81% 70.15% 10.08 24.94 14.37 333.61
52w 269.77 391.29

Perfil de dividendos

Frecuencia Trimestral Crecimiento (TTM) +5.8% CAGR 3a +7.1% +8.3% 14 años

Calendario de pagos

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

Histórico de dividendos

14 15 16 17 18 19 20 21 22 23 24 25

Dividendo por acción por año

Deuda y apalancamiento

623.75% 1.26 0.85 Deuda total 57.3B USD Efectivo total 12.0B USD 16.9B USD

Últimas cifras del balance publicadas.

En manos de 1 inversor

Regístrate para obtener un resumen con IA del dividendo de esta acción — y para seguirla en tu cartera.

Información, no asesoramiento financiero.

La información en Quantic se proporciona únicamente con fines informativos y educativos. Es de carácter general, no tiene en cuenta tu situación financiera personal y no constituye asesoramiento de inversión, financiero, fiscal o legal — ni una recomendación para comprar o vender ningún valor. Invertir conlleva riesgos, incluida la posible pérdida del capital; los resultados pasados no son un indicador fiable de los resultados futuros. Los datos de mercado provienen de proveedores terceros y pueden estar retrasados o ser inexactos. Antes de tomar cualquier decisión de inversión, considera tus objetivos, horizonte temporal, tolerancia al riesgo y diversificación, y consulta a un profesional financiero cualificado. Quantic no es un asesor financiero registrado ni un intermediario bursátil.

Quantic finance

Hecho con Elixir, Phoenix LiveView y Tailwind CSS

© 2026 Francesc Leveque · Aprender · Preguntas frecuentes